case_images: PMC10473406_01
case_images: Total colonoscopy images. (A-D) First procedure performed on January 9, 2022, showing mucosal redness, edema, granular change, and multiple small mucosal ulceration. (E-H) Second procedure performed on January 28, 2022, showing multiple deep oval ulcers (arrows).
case_images: JIR-16-3715-g0001.jpg
case_images: PMC10473406_01_JIR-16-3715-g0001.jpg
case_images: f0001
case_images: Following comprehensive history-taking, physical examination, and blood tests, he underwent colonoscopy, which revealed mucosal erythema, edema, granular changes, and multiple small mucosal ulcerations, and he was diagnosed with UC (Figures 1A-D). Repeat colonoscopy performed to further evaluate intestinal mucosal inflammation revealed several round, large, and oval deep ulcers throughout the colon (Figures 1E-H).
case_images: Abdominal CT scan findings. Image showing diffuse thickening of the colonic wall of ascending and descending colon (A) and sigmoid colon (B) (arrows), likely secondary to inflammation.
case_images: JIR-16-3715-g0002.jpg
case_images: PMC10473406_01_JIR-16-3715-g0002.jpg
case_images: f0002
case_images: Abdominal computed tomography (CT) revealed a thickened colonic wall with pericolonic exudates (Figure 2).  
case_images: Photographs showing skin lesions on the patient's arms, neck, and chest. (A) Initial Purple-erythematous infiltrating skin plaques on a photograph obtained on February 3. (B and C) Photograph obtained on February 6 (B) and on February 8 (C) showing progression of the skin lesions, presenting with bullous, papulovesicular, and pustular skin lesions.
case_images: JIR-16-3715-g0003.jpg
case_images: PMC10473406_01_JIR-16-3715-g0003.jpg
case_images: f0003
case_images: On the 6th day of admission, the patient had well-delineated, erythematous, and mildly tender plaques across the face, neck, trunk, arms, and hands, accompanied by fever (Tmax 38.5 C) (Figure 3A).
case_images: Photographs showing clinical remission of skin lesions after administration of IFX. (A) Skin lesions observed after the first cycle of IFX treatment. (B) Lesions observed before administration of the second cycle and, (C) Before administration of the third cycle of IFX therapy.
case_images: JIR-16-3715-g0004.jpg
case_images: PMC10473406_01_JIR-16-3715-g0004.jpg
case_images: f0004
case_images: The patient was discharged one week later and had no abdominal pain or bloody purulent stool, with significantly improved skin lesions (Figure 4A).  He was asymptomatic; the original skin lesions had subsided (Figure 4B), and he underwent routine blood tests (Table 1). He was asymptomatic, and residual pigmentation was observed at the site of the original skin lesions, with no new eruption (Figure 4C).